Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Income from Continuing Operations (2021 - 2025)

Senti Biosciences has reported Income from Continuing Operations over the past 5 years, most recently at 18539000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 16.33% year-over-year to 18539000.0; the TTM value through Dec 2025 reached 67852000.0, down 12.91%, while the annual FY2025 figure was 67852000.0, 12.92% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 18539000.0 at Senti Biosciences, down from 16782000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1178.0 in Q1 2021 and troughed at 43293000.0 in Q3 2023.
  • A 5-year average of 15272313.3 and a median of 15365500.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 997692.87% in 2022 and later surged 65.2% in 2024.
  • Year by year, Income from Continuing Operations stood at 3857088.0 in 2021, then tumbled by 306.16% to 15666000.0 in 2022, then dropped by 16.63% to 18272000.0 in 2023, then rose by 12.78% to 15937000.0 in 2024, then decreased by 16.33% to 18539000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SNTI at 18539000.0 in Q4 2025, 16782000.0 in Q3 2025, and 16528000.0 in Q2 2025.